Jordi Bruix
www.bclc.cat
0000-0002-9826-0753
197 papers found
Refreshing results…
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association
Outcome of liver cancer patients with SARS‐CoV‐2 infection: An International, Multicentre, Cohort Study
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules
Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival
Systemic treatment of hepatocellular carcinoma: An EASL position paper
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
Evolving role of regorafenib for the treatment of advanced cancers
Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma
Reply to: “The reported ‘clear cut time association between interferon-free treatment and HCC’ is anything but clear cut”
International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation
Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues
Reply to: “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules – A response”
Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma
Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis
Controversies in the management of hepatocellular carcinoma
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Medical treatment for cholangiocarcinoma
Missing publications? Search for publications with a matching author name.